Bone Density Assessment and Osteoporosis Management in Postmenopausal Women

T‑Score Interpretation

• Use the lowest T‑score obtained from lumbar spine, femoral neck, or total hip to classify bone density status (American College of Radiology) 1.
• Define bone density categories by T‑score:
  
  • Normal – T‑score ≥ ‑1.0
  • Osteopenia (low bone mass) – T‑score between ‑1.0 and ‑2.5
  • Osteoporosis – T‑score ≤ ‑2.5 (American College of Radiology) 1.
• For postmenopausal women and men > 50 years, diagnose osteoporosis using T‑scores rather than Z‑scores (American College of Radiology) 2.
• A fragility fracture of the hip, vertebra, proximal humerus, pelvis, or distal forearm establishes an osteoporosis diagnosis irrespective of the measured T‑score (American College of Radiology) 3.

Fracture Risk Assessment (FRAX)

• Calculate 10‑year major osteoporotic and hip fracture probabilities with the WHO FRAX tool, entering age, sex, BMI, femoral‑neck BMD (if available), prior fragility fracture, parental hip fracture, smoking status, glucocorticoid use (≥3 months at ≥5 mg prednisone daily), rheumatoid arthritis, secondary osteoporosis causes, and alcohol intake (≥3 drinks/day) (American College of Radiology) 1.

Treatment Initiation Criteria

• Initiate pharmacologic therapy when any of the following are present (American College of Physicians):
  
  • T‑score ≤ ‑2.5 at the lumbar spine, femoral neck, or total hip (American College of Physicians) 4.
  • History of a prior fragility fracture (hip, vertebral, proximal humerus, pelvis, or distal forearm) (American College of Physicians) 4.
  • Osteopenia (T‑score ‑1.0 to ‑2.5) plus a 10‑year FRAX hip fracture risk ≥ 3 % (American College of Physicians) 4.

First‑Line Pharmacologic Therapy

• Oral bisphosphonates are recommended as first‑line agents for most postmenopausal women with osteoporosis (American College of Physicians) 4.
  
  • Alendronate 70 mg orally once weekly.
  • Risedronate 35 mg orally once weekly or 150 mg once monthly.
• Administration instructions: take on an empty stomach with 8 oz of plain water, remain upright for 30–60 minutes, and wait at least 30 minutes before eating (American College of Physicians) 4.

Alternative Pharmacologic Options

• Denosumab 60 mg subcutaneously every 6 months is indicated when bisphosphonates are contraindicated (e.g., severe renal impairment, esophageal disorders) or not tolerated (American College of Radiology) 3.
• Critical warning: Upon discontinuation of denosumab, transition promptly to a bisphosphonate to avoid rebound vertebral fractures caused by rapid bone loss (American College of Radiology) 3.

Agents to Avoid

• Menopausal estrogen therapy, estrogen + progestogen, and raloxifene should not be used for osteoporosis treatment because their benefit‑to‑harm ratios are inferior to bisphosphonates (American College of Physicians) 4.

Non‑Pharmacologic Management (Universal)

• Calcium intake 1,000–1,200 mg daily (dietary plus supplement) (American College of Radiology) 3.
• Vitamin D supplementation 800–1,000 IU daily (American College of Radiology) 3.
• Weight‑bearing exercise ≥30 minutes on most days (American College of Radiology) 3.
• Fall‑prevention strategies: home safety assessment, balance training, vision correction (American College of Radiology) 2.
• Mandatory smoking cessation counseling (American College of Radiology) 3.
• Limit alcohol to fewer than 3 drinks per day (American College of Radiology) 3.

Evaluation for Secondary Causes

• Prior to treatment, obtain laboratory studies to identify reversible secondary osteoporosis: serum 25‑hydroxyvitamin D, calcium, phosphorus, parathyroid hormone, thyroid‑stimulating hormone, complete blood count, and comprehensive metabolic panel (including creatinine and liver enzymes) (American College of Radiology) 5.
• Secondary causes are identified in 44 %–90 % of postmenopausal women with osteoporosis, most commonly vitamin D deficiency, primary hyperparathyroidism, hyperthyroidism (including iatrogenic excess levothyroxine), and chronic glucocorticoid use (American College of Radiology) 5.

Monitoring Strategy

• Routine BMD testing is not recommended during the first 5 years of pharmacologic therapy because evidence does not show outcome benefit (American College of Physicians) 4.
• If BMD monitoring is clinically indicated (e.g., suspected non‑adherence or secondary cause):
  
  • Repeat DXA in 1–2 years using the same scanner and protocol (American College of Radiology) 3.
  • Compare absolute BMD values (g/cm²), not T‑ or Z‑scores (American College of Radiology) 2.
  • Consider changes only if they exceed the facility’s least significant change (typically 3 %–5 %) (American College of Radiology) 3.
• Perform baseline vertebral fracture assessment (VFA) imaging because asymptomatic vertebral fractures are the strongest predictor of future fractures (American College of Radiology) 3.

Clinical Pitfalls to Avoid

• Do not diagnose osteoporosis in premenopausal women or men < 50 years using T‑scores; use Z‑scores instead (American College of Radiology) 2.
• Do not rely solely on T‑scores without FRAX calculation for osteopenic patients, as many fractures occur within the osteopenic range (American College of Radiology) 2.
• Do not use lumbar‑spine BMD measurements in patients with existing vertebral fractures, severe osteoarthritis, or aortic calcification because these conditions can falsely elevate BMD values (American College of Radiology) 1.
• Do not continue denosumab indefinitely without a planned transition to a bisphosphonate, as abrupt discontinuation leads to rapid bone loss and increased fracture risk (American College of Radiology) 3.

Osteoporosis Screening, Diagnosis, and Management in Postmenopausal Women

Screening Recommendations

• Universal DXA screening for all postmenopausal women aged ≥ 65 years at the hip and lumbar spine, irrespective of additional risk factors. (Society: American College of Radiology) 6, 7, 8
• Targeted DXA screening for postmenopausal women aged 50–64 years who have at least one extra risk factor (e.g., low body weight, parental hip fracture, current smoking, excess alcohol). (Society: American College of Radiology) 6
• Immediate DXA and prompt treatment initiation for any woman with a fragility fracture, regardless of age. (Society: American College of Radiology) 6
• Dual‑energy X‑ray absorptiometry (DXA) at central sites (total hip, femoral neck, lumbar spine) is the sole acceptable screening modality and is considered the gold standard. (Society: American College of Radiology) 6, 7
• DXA delivers low radiation exposure and its BMD values correlate directly with bone strength and future fracture risk. (Society: American College of Radiology) 6
• BMD should be measured at all three central sites because fracture risk for a specific skeletal region is best predicted by the BMD of that same region. (Society: American College of Radiology) 6

Diagnostic Criteria (T‑Score Classification)

• Normal bone density: T‑score ≥ ‑1.0 at any measured site. (Society: International Osteoporosis Foundation) 9
• Osteopenia (low bone mass): T‑score between ‑1.0 and ‑2.5. (Society: International Osteoporosis Foundation) 9
• Osteoporosis: T‑score ≤ ‑2.5 at the hip or spine, using the lowest T‑score among lumbar spine, femoral neck, or total hip. (Society: International Osteoporosis Foundation; reinforced by JAMA guideline) 9, 6

Fracture Risk Assessment (FRAX)

• The WHO FRAX tool calculates 10‑year probability of major osteoporotic and hip fractures by incorporating age, sex, body‑mass index, femoral‑neck BMD (when available), prior fragility fracture, parental hip fracture, smoking status, glucocorticoid use, rheumatoid arthritis, secondary osteoporosis causes, and alcohol intake (≥3 drinks/day). (Society: American College of Radiology) 6

Identification of Secondary Osteoporosis Causes

• Primary hyperparathyroidism is a common reversible secondary cause of osteoporosis in postmenopausal women. (Society: American College of Radiology) 6
• Malabsorption disorders also contribute significantly to secondary osteoporosis. (Society: International Osteoporosis Foundation) 9

Common Pitfalls to Avoid

• Do not diagnose osteoporosis in premenopausal women or men < 50 years using T‑scores; instead, use Z‑scores, with a Z‑score ≤ ‑2.0 considered abnormal. (Society: International Osteoporosis Foundation) 9
• Do not rely on peripheral DXA, quantitative CT, or other imaging modalities for diagnosis; only central DXA of hip and spine is acceptable. (Society: American College of Radiology) 6, 7
• Do not screen postmenopausal women younger than 50 years unless they have sustained a fragility fracture or possess specific high‑risk conditions. (Society: American College of Radiology) 6